FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760184568> ?p ?o ?g. }

• W2760184568 endingPage "E180" @default.
• W2760184568 startingPage "E180" @default.
• W2760184568 abstract "To evaluate the efficacy of stereotactic body radiation therapy (SBRT) with and or without sorafenib for advance hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). We retrospectively analyzed 54 HCC patients with PVTT treated with Cyberknife SBRT between January 2009 and June 2016. Of these, Sorafenib was given after SBRT to 18 patients and SBRT alone was given to 35 patients. SBRT was designed to target the liver tumor and tumor thrombosis, radiation dose range from 36-45 Gy (median 40 Gy) in 3-5 fractions : The mean follow-up for SBRT with sorafenib and SBRT alone were 13.22±10.07 months and 15.33.±22.01 months, respectively. At the time of analysis, response rate was comparable in both group. CR and PR was 77.77 % for SBRT with Sorafenib vs 75.00 % for those without. (p=0.4308). The median progression-free survival rate was 6 months (2-11 mos) vs 3 months (2-5.6mos) (p=0.2397). And the 6 months, 1- and 2-yrs. progression-free survival rate were 61.1 %, 25.7 % and 15.2 % vs 30.6 %, 11.1 % and 8.3 % for SBRT with Sorafenib and without Sorafenib group. (p=0.1225), there was a trends of benefit for overall survival rate for those with Sorafenib group. the median , 6 months, 1- and 2-years overall survival rate for SBRT with Sorafenib were 12.5 months (6-15 mos.), 77.8 %, 55.6 % and 17.7 % , respectively. While for those without Sorafenib were 7 months (5-13.5 mos.), 63.9 % , 33.3 % and 11.1 % (p=0.2804), respectively. No patient experienced > grade 3 toxicity. Although the median survival, 6 months, 1- and 2-yrs Overall survival and Progression free survival rate for SBRT with Sorafenib group were better than those in SBRT alone group. However , the trends did not reach statistical significance. ECOG status, tumor type, PVTT involving the bilateral branch and main trunk were the major factors affecting prognosis in both group. The practical advantage of SBRT with or without Sorafenib are of particular interest for such poor prognosis patients. Large scale and randomized study is further needed to define the benefit of Sorafenib on SBRT patient with portal vein tumor thrombosis.." @default.
• W2760184568 created "2017-10-06" @default.
• W2760184568 creator A5007919135 @default.
• W2760184568 creator A5016960195 @default.
• W2760184568 creator A5030960192 @default.
• W2760184568 creator A5039394836 @default.
• W2760184568 creator A5041208059 @default.
• W2760184568 creator A5082111148 @default.
• W2760184568 date "2017-10-01" @default.
• W2760184568 modified "2023-09-26" @default.
• W2760184568 title "A Preliminary Analysis of Robotic Radiosurgery Stereotactic Body Radiation Therapy With or Without Sorafenib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis" @default.
• W2760184568 doi "https://doi.org/10.1016/j.ijrobp.2017.06.1033" @default.
• W2760184568 hasPublicationYear "2017" @default.
• W2760184568 type Work @default.
• W2760184568 sameAs 2760184568 @default.
• W2760184568 citedByCount "0" @default.
• W2760184568 crossrefType "journal-article" @default.
• W2760184568 hasAuthorship W2760184568A5007919135 @default.
• W2760184568 hasAuthorship W2760184568A5016960195 @default.
• W2760184568 hasAuthorship W2760184568A5030960192 @default.
• W2760184568 hasAuthorship W2760184568A5039394836 @default.
• W2760184568 hasAuthorship W2760184568A5041208059 @default.
• W2760184568 hasAuthorship W2760184568A5082111148 @default.
• W2760184568 hasBestOaLocation W27601845681 @default.
• W2760184568 hasConcept C126322002 @default.
• W2760184568 hasConcept C126838900 @default.
• W2760184568 hasConcept C143998085 @default.
• W2760184568 hasConcept C2776651944 @default.
• W2760184568 hasConcept C2778019345 @default.
• W2760184568 hasConcept C2778695046 @default.
• W2760184568 hasConcept C2778800853 @default.
• W2760184568 hasConcept C2780387249 @default.
• W2760184568 hasConcept C2780868729 @default.
• W2760184568 hasConcept C2989005 @default.
• W2760184568 hasConcept C509974204 @default.
• W2760184568 hasConcept C71924100 @default.
• W2760184568 hasConceptScore W2760184568C126322002 @default.
• W2760184568 hasConceptScore W2760184568C126838900 @default.
• W2760184568 hasConceptScore W2760184568C143998085 @default.
• W2760184568 hasConceptScore W2760184568C2776651944 @default.
• W2760184568 hasConceptScore W2760184568C2778019345 @default.
• W2760184568 hasConceptScore W2760184568C2778695046 @default.
• W2760184568 hasConceptScore W2760184568C2778800853 @default.
• W2760184568 hasConceptScore W2760184568C2780387249 @default.
• W2760184568 hasConceptScore W2760184568C2780868729 @default.
• W2760184568 hasConceptScore W2760184568C2989005 @default.
• W2760184568 hasConceptScore W2760184568C509974204 @default.
• W2760184568 hasConceptScore W2760184568C71924100 @default.
• W2760184568 hasIssue "2" @default.
• W2760184568 hasLocation W27601845681 @default.
• W2760184568 hasOpenAccess W2760184568 @default.
• W2760184568 hasPrimaryLocation W27601845681 @default.
• W2760184568 hasRelatedWork W1967342431 @default.
• W2760184568 hasRelatedWork W2017527224 @default.
• W2760184568 hasRelatedWork W2036151570 @default.
• W2760184568 hasRelatedWork W2412087595 @default.
• W2760184568 hasRelatedWork W2471901561 @default.
• W2760184568 hasRelatedWork W2526999821 @default.
• W2760184568 hasRelatedWork W2760184568 @default.
• W2760184568 hasRelatedWork W2953263120 @default.
• W2760184568 hasRelatedWork W3203016989 @default.
• W2760184568 hasRelatedWork W4233433391 @default.
• W2760184568 hasVolume "99" @default.
• W2760184568 isParatext "false" @default.
• W2760184568 isRetracted "false" @default.
• W2760184568 magId "2760184568" @default.
• W2760184568 workType "article" @default.